Meeting
2019 ASCO Annual Meeting
Biomarker predictors of outcome from a randomized trial of nivolumab +/- stereotactic body radiotherapy (SBRT) in metastatic (M1) head and neck squamous cell carcinoma (HNSCC).
Authors
Sean Matthew McBride
Memorial Sloan Kettering Cancer Center, New York, NY
Sean Matthew McBride , Nancy Y. Lee , David G. Pfister , Eric Jeffrey Sherman , C. Jillian Tsai , Jahan Aghalar , Juliana Eng , Wanqing Iris Zhi , Daniel Curtis McFarland , Loren S. Michel , Lara Dunn , Alan Loh Ho , Nadeem Riaz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02684253
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6063)
DOI
10.1200/JCO.2019.37.15_suppl.6063
Abstract #
6063
Poster Bd #
52
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2024 ASCO Annual Meeting
Genomic characteristics of exceptional responders to treatment with PD-1 inhibitors in refractory/metastatic head and neck squamous cell carcinoma.
First Author: Mark Chang
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
First Author: Ruoyu Miao
Poster
2022 ASCO Annual Meeting
Nivolumab timing as a major survival predictor in patients with stage IV non–small cell lung cancer.
First Author: Abdoulaye Karaboué